GlassScriptPhysician profile
David H Posner
NPI 1982794848
$13,424.24
in general payments reported to CMS, 2019-2025
30 companies · $2,124 in 2025
The $2,124 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,718 · 2020: $1,364 · 2021: $1,616 · 2022: $1,962 · 2023: $2,111 · 2024: $2,529 · 2025: $2,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,665 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,664.64 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,133.32 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $2,854.98 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,635.18 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Insmed, INC. | $965.45 | 2019-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $929.70 | 2021-2025 | Dupixent |
| Genzyme Corporation | $653.76 | 2019-2024 | |
| Mylan Specialty L.P. | $595.95 | 2019-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $501.92 | 2021-2025 | Acthar |
| Amgen INC. | $464.68 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $301.62 | 2019-2022 | |
| Electromed, INC. | $176.51 | 2023-2025 | Smartvest |
| Novartis Pharmaceuticals Corporation | $152.28 | 2019-2024 | |
| Baxter Healthcare | $137.28 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Teva Pharmaceuticals USA, INC. | $130.39 | 2021-2022 | |
| Verona Pharma, INC. | $121.78 | 2025 | Ohtuvayre |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $115.76 | 2020-2025 | Glassia |
| Advanced Respiratory, INC | $92.75 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $73.29 | 2019 | |
| Paratek Pharmaceuticals, INC. | $59.87 | 2020-2025 | Nuzyra |
| Ani Pharmaceuticals, INC. | $58.54 | 2025 | Purified Cortrophin Gel |
| Philips North America LLC | $42.72 | 2022 | |
| Merck Sharp & Dohme LLC | $39.43 | 2020-2022 | |
| Amarin Pharma, INC. | $34.75 | 2019 | |
| Pfizer INC. | $32.85 | 2019-2025 | |
| United Therapeutics Corporation | $26.86 | 2021 | |
| Abbvie INC. | $24.46 | 2019 | |
| Eisai INC. | $21.60 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.65 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $17.36 | 2025 | Uptravi, Opsumit |
| Circassia INC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Posner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.